film-coated tablets
Sponsors
Medical University Of Lodz, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Centro Cardiologico Monzino S.p.A., Stichting Amsterdam UMC, Exelixis Inc.
Conditions
Acute Myeloid LeucaemiaArrhythmogenic Cardiomyopathy (ACM)Cardiometabolic disease and mild chronic hyperuricemiaChronic kidney disease in paediatric patientsFibrodyplasia Ossificans Progressiva (FOP)Metastatic Medullary Thyroid CancerPatients with
- Stable peripheral artery disease
and
- Asymptomaticatherosclerotic plaque/stenosis in the carotid artery;
asymptomatic regarding cerebral ischaemia including stroke and
transient ischaemic attack (TIA) or amaurosis fugax.
Phase 2
Statin Effect on ARrhythmogenic CardiomyopatHy disease progression
RecruitingCTIS2024-514643-28-00
Start: 2025-03-25Target: 102Updated: 2025-04-14
Saracatinib trial TO Prevent FOP (STOPFOP)
Active, not recruitingCTIS2024-515186-33-00
Start: 2020-01-08Target: 18Updated: 2025-12-01
Xanthine Oxidoreductase Inhibition with Febuxostat in Adults with Mild Hyperuricaemia and Impaired Glucose Metabolism: a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial in a Prespecified Uric Acid Overproduction Phenotype (XO-FACTOR)
WithdrawnCTIS2026-526401-15-00
Target: 248Updated: 2026-10-19
Phase 3
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
RecruitingCTIS2023-503394-37-00
Start: 2024-10-23Target: 520Updated: 2025-10-15
Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS)
Not yet recruitingCTIS2024-518539-13-00
Target: 62Updated: 2024-10-27
A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets in paediatric patients with chronic kidney disease (EMPA-KIDNEY Kids)
RecruitingCTIS2024-512577-27-00
Start: 2025-12-02Target: 55Updated: 2025-11-17